Ashcroft F M
University Laboratory of Physiology, Oxford, U.K.
Horm Metab Res. 1996 Sep;28(9):456-63. doi: 10.1055/s-2007-979837.
Sulfonylureas are widely used to treat non-insulin dependent diabetes mellitus. These drugs exert their hypoglycaemic effects by stimulating insulin secretion from the pancreatic beta-cell. Their primary mechanism of action is to close ATP-sensitive K-channels in the beta-cell plasma membrane, and so initiate a chain of events which results in insulin release. Recent studies have shown that the beta-cell ATP-sensitive K-channel is a complex of two proteins: a pore-forming subunit (Kir6.2) and a drug-binding subunit (SUR1) which functions as the receptor for sulfonylureas. This review summarizes recent advances in our understanding of the molecular mechanism of sulfonylurea action, focusing on the relationship between the sulfonylurea receptor and the K-ATP channel. Earlier studies are also re-examined in the light of new findings.
磺脲类药物被广泛用于治疗非胰岛素依赖型糖尿病。这些药物通过刺激胰腺β细胞分泌胰岛素发挥降糖作用。其主要作用机制是关闭β细胞质膜上的ATP敏感性钾通道,从而引发一系列导致胰岛素释放的事件。最近的研究表明,β细胞ATP敏感性钾通道是由两种蛋白质组成的复合物:一个形成孔道的亚基(Kir6.2)和一个作为磺脲类药物受体发挥作用的药物结合亚基(SUR1)。本综述总结了我们对磺脲类药物作用分子机制理解的最新进展,重点关注磺脲类药物受体与钾离子ATP通道之间的关系。还根据新发现重新审视了早期研究。